Richard Gregory

Chairman of the SAB. Dr. Gregory has been an independent consultant to biopharma companies since September 2019. He is the co-author of over 60 peer-reviewed publications and 23 issued U.S. patents in the area of biotechnology. He is a Fellow of the American Institute for Medical and Biological Engineering. Dr. Gregory worked in ImmunoGen from 2015 for 4 years and was responsible for research leading to new antibody-based therapeutics to address the unmet needs of patients with cancer. Prior to that, he worked for Genzyme Corporation where he spent 25 years in positions of increasing responsibility. In 1990, his group at Genzyme was the first to express the cystic fibrosis transmembrane conductance regulator (CFTR) protein and to determine the molecular defect caused by the most common mutation of CFTR. This work led to the founding of Genzyme’s gene therapy platform, which Dr. Gregory led until 2001. He then became Senior Vice President and Head of Research for Genzyme Corporation leading early R&D, from discovery to development, in all therapeutic areas and platforms. In 2011, following the acquisition of Genzyme, Dr. Gregory was appointed Head of the Sanofi-Genzyme R&D Center. He received his Ph.D in Biochemistry from the University of Massachusetts at Amherst in 1986, followed by post-doctoral research in cancer genetics at the Worcester Foundation for Experimental Biology.